Cargando…
Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
This study compares the efficacy, safety, and patient-reported outcomes of three intraocular implants (IOL): Tecnis Synergy IOL, AcrySof IQ PanOptix Trifocal, and Tecnis Symfony EDOF IOL. Participants achieving 20/20 or better uncorrected binocular visual acuity were as follows: Synergy—67% distance...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342887/ https://www.ncbi.nlm.nih.gov/pubmed/37445400 http://dx.doi.org/10.3390/jcm12134365 |
_version_ | 1785072606692507648 |
---|---|
author | Moshirfar, Majid Stoakes, Isabella M. Theis, Joshua S. Porter, Kaiden B. Santos, Jordan M. Martheswaran, Tanisha Payne, Carter J. Hoopes, Phillip C. |
author_facet | Moshirfar, Majid Stoakes, Isabella M. Theis, Joshua S. Porter, Kaiden B. Santos, Jordan M. Martheswaran, Tanisha Payne, Carter J. Hoopes, Phillip C. |
author_sort | Moshirfar, Majid |
collection | PubMed |
description | This study compares the efficacy, safety, and patient-reported outcomes of three intraocular implants (IOL): Tecnis Synergy IOL, AcrySof IQ PanOptix Trifocal, and Tecnis Symfony EDOF IOL. Participants achieving 20/20 or better uncorrected binocular visual acuity were as follows: Synergy—67% distance, 64% intermediate, and 47% near; PanOptix—73% distance, 73% intermediate, and 50% near; and Symfony—63% distance, 75% intermediate, and 22% near. Symfony demonstrated superior intermediate visual acuity compared to Synergy (p = 0.0182) for those achieving 20/25 or better. Both Synergy and PanOptix showed superiority over Symfony for near visual acuity (p < 0.0001). Halos were statistically more common in Synergy participants compared to PanOptix (p = 0.0013) and Symfony (p < 0.0001). Each trial lens outperformed its monofocal IOL in terms of independence from glasses or contacts, with Synergy and PanOptix showing statistical significance over Symfony. Comparing contrast sensitivities and defocus curves was challenging due to data variance and as such, standardization of United States Food and Drug Administration (US-FDA) data reporting is key for better comparison of outcomes among different IOL platforms. |
format | Online Article Text |
id | pubmed-10342887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103428872023-07-14 Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery Moshirfar, Majid Stoakes, Isabella M. Theis, Joshua S. Porter, Kaiden B. Santos, Jordan M. Martheswaran, Tanisha Payne, Carter J. Hoopes, Phillip C. J Clin Med Article This study compares the efficacy, safety, and patient-reported outcomes of three intraocular implants (IOL): Tecnis Synergy IOL, AcrySof IQ PanOptix Trifocal, and Tecnis Symfony EDOF IOL. Participants achieving 20/20 or better uncorrected binocular visual acuity were as follows: Synergy—67% distance, 64% intermediate, and 47% near; PanOptix—73% distance, 73% intermediate, and 50% near; and Symfony—63% distance, 75% intermediate, and 22% near. Symfony demonstrated superior intermediate visual acuity compared to Synergy (p = 0.0182) for those achieving 20/25 or better. Both Synergy and PanOptix showed superiority over Symfony for near visual acuity (p < 0.0001). Halos were statistically more common in Synergy participants compared to PanOptix (p = 0.0013) and Symfony (p < 0.0001). Each trial lens outperformed its monofocal IOL in terms of independence from glasses or contacts, with Synergy and PanOptix showing statistical significance over Symfony. Comparing contrast sensitivities and defocus curves was challenging due to data variance and as such, standardization of United States Food and Drug Administration (US-FDA) data reporting is key for better comparison of outcomes among different IOL platforms. MDPI 2023-06-28 /pmc/articles/PMC10342887/ /pubmed/37445400 http://dx.doi.org/10.3390/jcm12134365 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moshirfar, Majid Stoakes, Isabella M. Theis, Joshua S. Porter, Kaiden B. Santos, Jordan M. Martheswaran, Tanisha Payne, Carter J. Hoopes, Phillip C. Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery |
title | Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery |
title_full | Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery |
title_fullStr | Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery |
title_full_unstemmed | Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery |
title_short | Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery |
title_sort | assessing visual outcomes: a comparative study of us-fda premarket approval data for multifocal and edof lens implants in cataract surgery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342887/ https://www.ncbi.nlm.nih.gov/pubmed/37445400 http://dx.doi.org/10.3390/jcm12134365 |
work_keys_str_mv | AT moshirfarmajid assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery AT stoakesisabellam assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery AT theisjoshuas assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery AT porterkaidenb assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery AT santosjordanm assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery AT martheswarantanisha assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery AT paynecarterj assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery AT hoopesphillipc assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery |